TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF

Telix Pharmaceuticals Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026

$10.74+0.05 (+0.47%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Telix Pharmaceuticals Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	804	517	333	–
Cost of Revenue	377	180	123	–
Gross Profit	426	336	210	–
Research & Development	171	128	85	–
Selling & Marketing	97	56	33	–
Operating Income	30	55	11	–
Interest Expense	41	24	9.09	–
Interest & Investment Income	5.83	7.18	0.67	–
Pretax Income	-5.27	38	2.59	–
Income Tax Expense	1.86	4.23	-1.61	–
Net Income incl. Noncontrolling Interests	-7.13	34	4.21	–
Net Income	-7.13	34	4.21	–
EPS (Basic)(per share)	-0.02	0.10	0.01	–
EPS (Diluted)(per share)	-0.02	0.10	0.01	–
Shares Outstanding (Basic, Weighted)(shares)	338	331	319	311
Shares Outstanding (Diluted, Weighted)(shares)	338	345	324	311
EBITDA	51	60	15	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 53.1%
Operating margin: 3.7%
Net margin: -0.9%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.01
Debt to equity: –
Debt to assets: 37.9%
Cash to current liabilities: 103.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –